Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Sarah, Djabarouti"'
Autor:
Jérémy Chambord, Bertrand Chauveau, Sarah Djabarouti, Jean Vignaud, Benjamin Taton, Karine Moreau, Jonathan Visentin, Pierre Merville, Fabien Xuereb, Lionel Couzi
Publikováno v:
Transplant International, Vol 36 (2023)
Our objective was to calculate an immunosuppressant possession ratio (IPR) to diagnose non-adherence at the time of antibody-mediated rejection (ABMR). IPR was defined as the ratio of number of pills collected at the pharmacy to the number of pills p
Externí odkaz:
https://doaj.org/article/84dc2167df0f4626acac1101697dcbaf
Autor:
Jeremy Chambord, Lionel Couzi, Pierre Merville, Karine Moreau, Fabien Xuereb, Sarah Djabarouti
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 12 (2021)
Aims: To assess the effect of a pharmacist-led intervention, using Barrows cards method, during the first year after renal transplantation, on patient knowledge about their treatment, medication adherence and exposure to treatment in a French cohort.
Externí odkaz:
https://doaj.org/article/7433b22d08564508a7579b1e8dda36d9
Autor:
Julien, Carvelli, Ferhat, Meziani, Jean, Dellamonica, Pierre-Yves, Cordier, Jerome, Allardet-Servent, Megan, Fraisse, Lionel, Velly, Saber Davide, Barbar, Samuel, Lehingue, Christophe, Guervilly, Maxime, Desgrouas, Fabrice, Camou, Christelle, Piperoglou, Frederic, Vely, Olivier, Demaria, Joyson, Karakunnel, Joanna, Fares, Luciana, Batista, Federico, Rotolo, Julien, Viotti, Agnes, Boyer-Chammard, Karine, Lacombe, Erwan, Le Dault, Michel, Carles, Nicolas, Schleinitz, Eric, Vivier, Sarah, Djabarouti
Publikováno v:
Critical Care Medicine
Critical Care Medicine, 2022, 50, pp.1788-1798. ⟨10.1097/ccm.0000000000005683⟩
Critical Care Medicine, 2022, 50, pp.1788-1798. ⟨10.1097/ccm.0000000000005683⟩
International audience; OBJECTIVES: Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19. DESIGN: FOR COVID Elimination (FORCE) was a double-bl
Autor:
Audrey Lehmann, Laurent Flet, Hélène Bourgoin, Audrey Castet, Laetitia Caturla, Amélie Cransac, Sarah Djabarouti, Frédéric Eyvrard, Anaïs Grand, Corinne Guérin, Mélanie Minoves, Françoise Renon-Carron, Lise Bernard
Publikováno v:
Le Pharmacien Clinicien
Le Pharmacien Clinicien, 2022, 57 (4), pp.328-335. ⟨10.1016/j.phacli.2022.05.002⟩
Le Pharmacien Clinicien, 2022, 57 (4), pp.328-335. ⟨10.1016/j.phacli.2022.05.002⟩
Background and objectivesThe hospital pharmacist, in charge of the pharmaceutical aspects of clinical trials plays a central role in the management and the proper use of investigational health products (IHP), in accordance with the Good Clinical Prac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8301f41078be141f9099ae31d970338c
https://hal.science/hal-04012007
https://hal.science/hal-04012007
Autor:
Alexandre Duvignaud, Edouard Lhomme, Racha Onaisi, Rémi Sitta, Ambre Gelley, Julie Chastang, Lionel Piroth, Christine Binquet, Julie Dupouy, Alain Makinson, Benjamin Lefèvre, Jean-Marc Naccache, Caroline Roussillon, Roland Landman, Cédrick Wallet, Sophie Karcher, Valérie Journot, Duc Nguyen, Thierry Pistone, Stéphane Bouchet, Marie-Edith Lafon, Mathieu Molimard, Rodolphe Thiébaut, Xavier de Lamballerie, Jean-Philippe Joseph, Laura Richert, Olivier Saint-Lary, Sarah Djabarouti, Linda Wittkop, Xavier Anglaret, Denis Malvy
Publikováno v:
Clinical Microbiology and Infection
Clinical Microbiology and Infection, 2022, 28 (7), pp.1010-1016. ⟨10.1016/j.cmi.2022.02.031⟩
Clinical Microbiology and Infection, 2022, 28 (7), pp.1010-1016. ⟨10.1016/j.cmi.2022.02.031⟩
International audience; Objectives: To assess the efficacy of inhaled ciclesonide in reducing the risk of adverse outcomes in COVID-19 outpatients at risk of developing severe illness.Methods: COVERAGE is an open-label, randomized controlled trial. O
Autor:
R. Legeron, Sybille De-Germay, Guillaume Bouguéon, Sylvie Crauste-Manciet, Jean-Marc Bernadou, Sarah Djabarouti, Aude Berroneau, F. Xuereb
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(9)
Purpose To investigate the long-term chemical and physical stability of 5-mg/mL acyclovir solution in polypropylene bags stored at 5°C ± 3°C for 2 months in order to determine the feasibility of batch production by a centralized intravenous additi
Autor:
F. Xuereb, M. Bonnin, Dominique Breilh, Julien Ollivier, Sarah Djabarouti, V. Servant, A. Berroneau, V. Maurin, A. de Coucy, R. Legeron, F. Picard, M. Megne Wabo
Publikováno v:
Le Pharmacien Hospitalier et Clinicien
Le Pharmacien Hospitalier et Clinicien, Elsevier, A paraître, 2 (52), pp.367-376
Le Pharmacien Hospitalier et Clinicien, Elsevier, A paraître, 2 (52), pp.367-376
IntroductionSacubitril/valsartan, a new treatment for chronic cardiac failure, has been available only in retrocession from approved pharmacies since it obtained market authorization. A specific communication pathway (pharmaceutic interview and hospi
Autor:
Stephanie Bourget, Johanna Berdugo, Martine Pennetier, Laure Gutermann, Yann Fardini, Sarah Djabarouti, François Stephan, Pierre Clerson, Bruce A. Schwartz
Publikováno v:
Blood. 136:4-5
Introduction: Fibrinogen deficiency can be either congenital, or acquired due to situations such as trauma, excessive surgical bleeding, or post-partum hemorrhage (PPH). Transfusion of human fibrinogen concentrate (HFC) can correct this deficiency, p
Autor:
F. Xuereb, R. Legeron, Cédric Carrié, Julien Ollivier, M Biais, Sarah Djabarouti, Nicolas d'Houdain, Laurent Petit, Dominique Breilh
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, In press, 63 (3), pp.e02134-18. ⟨10.1128/AAC.02134-18⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, In press, 63 (3), pp.e02134-18. ⟨10.1128/AAC.02134-18⟩
The objective of the present study was to determine whether augmented renal clearance (ARC) impacts negatively on ceftriaxone pharmacokinetic (PK)/pharmacodynamic (PD) target attainment in critically ill patients. Over a 9-month period, all criticall
Autor:
Jean-François Viallard, Jean-Luc Pellegrin, Dominique Breilh, R. Legeron, Caroline Streicher, F. Xuereb, Estibaliz Lazaro, C. Greib, Sarah Djabarouti, Stéphane Bouchet
Publikováno v:
British Journal of Clinical Pharmacology. 78:1419-1425
Aim To date, neither the benefit of mycophenolic acid (MPA) therapeutic drug monitoring (TDM), the prodrug of mycophenolate mofetil (MMF), nor the optimal monitoring technique have been established in autoimmune diseases. This study was undertaken to